ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1040 participants.
Also called NCT05672836
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,040 participants
- Registry
-
NCT05672836
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT05672836. Randomized; quadruple masking; primary purpose treatment. Start 2024-12-18 (actual); primary completion 2028-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement
- Acronym
- ENAVO-TAVR
- Condition
- Aortic Valve Stenosis
- Condition
- Heart Failure
- Intervention (Drug)
- Enavogliflozin
- Intervention (Drug)
- Standard-of-Care
- Lead sponsor
- Duk-Woo Park, MD
- Collaborator
- CardioVascular Research Foundation, Korea
- Collaborator
- Daewoong Pharmaceutical Co. LTD.
Record details
- Record id
cardio:ct-nct05672836- Content hash
26fc113f7dc346676098e8767a81515d25695900eb5340e4aaefa6bb9a2cae85